tiprankstipranks
Trending News
More News >
Amplia Therapeutics Ltd. (AU:ATX)
:ATX
Advertisement

Amplia Therapeutics (ATX) AI Stock Analysis

Compare
20 Followers

Top Page

AU:ATX

Amplia Therapeutics

(OTC:ATX)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
Amplia Therapeutics faces significant financial challenges typical of a biotech in development, with strong gross margins but ongoing losses and negative cash flows. Technical indicators suggest bearish momentum, and the valuation reflects high risk due to negative earnings. Investors should be cautious, balancing potential growth against financial risks.

Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)

Amplia Therapeutics Business Overview & Revenue Model

Company DescriptionAmplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.
How the Company Makes MoneyAmplia Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company's revenue model includes funding from grants and research partnerships, which support the clinical development of its therapies. Additionally, Amplia may enter into licensing agreements or partnerships with larger pharmaceutical companies, allowing them to share in the development costs and potential profits from successful drug candidates. Revenue can also be derived from milestone payments and royalties based on sales once products are commercialized. Furthermore, the company may attract investment through equity financing to support its ongoing research and development efforts.

Amplia Therapeutics Financial Statement Overview

Summary
Amplia Therapeutics shows strong gross margins and revenue growth typical for a biotech firm in development, but ongoing losses and negative cash flows highlight profitability challenges. The balance sheet is stable with low leverage, but cash flow issues persist.
Income Statement
45
Neutral
Amplia Therapeutics shows a mixed performance in its income statement. The company has a strong gross profit margin, consistently above 90%, indicating efficient cost management. However, the net profit margin is negative, reflecting ongoing losses, which is common in the biotechnology industry due to high R&D expenses. Revenue growth is positive, but the company has not yet achieved profitability, as evidenced by negative EBIT and EBITDA margins.
Balance Sheet
50
Neutral
The balance sheet of Amplia Therapeutics is relatively stable, with a low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is healthy, showing a strong equity position relative to total assets, which provides a buffer against financial instability.
Cash Flow
40
Negative
Amplia Therapeutics faces challenges in its cash flow statement. The company has negative operating and free cash flows, which are typical for biotech firms in the development stage. The free cash flow to net income ratio is close to 1, indicating that cash outflows are closely aligned with reported losses. Despite a significant increase in free cash flow growth, the overall cash flow position remains weak.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.78M3.78M4.45M1.19M1.98M1.53M
Gross Profit3.57M3.57M4.01M1.12M1.98M1.53M
EBITDA-6.78M-6.78M-8.78M-7.26M-3.64M-3.81M
Net Income-6.57M-6.57M-4.50M-6.24M-3.64M-2.28M
Balance Sheet
Total Assets22.94M22.94M14.85M18.68M24.48M10.88M
Cash, Cash Equivalents and Short-Term Investments10.86M10.86M3.39M9.26M14.61M1.85M
Total Debt13.89K13.89K1.59M2.27M2.10M0.00
Total Liabilities1.91M1.91M3.43M2.85M2.64M539.13K
Stockholders Equity21.02M21.02M11.42M15.84M21.85M10.34M
Cash Flow
Free Cash Flow-6.89M-6.89M-5.13M-5.31M-4.42M-2.92M
Operating Cash Flow-6.89M-6.89M-5.13M-5.29M-4.40M-2.92M
Investing Cash Flow-2.07K-2.07K-2.23K-58.42K-26.64K-5.35K
Financing Cash Flow14.32M14.32M-772.98K-84.22K17.19M3.66M

Amplia Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.14
Price Trends
50DMA
0.16
Negative
100DMA
0.19
Negative
200DMA
0.13
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
42.27
Neutral
STOCH
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and above the 200-day MA of 0.13, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.27 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ATX.

Amplia Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU$14.28M-143.71%306.88%
AU$69.26M-41.60%4.07%
AU$16.40M-7.65-1651.76%-100.00%2.86%
AU$6.62M-628.72%31.87%
AU$27.18M-5.57-157.93%-36.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ATX
Amplia Therapeutics
0.14
<0.01
2.27%
AU:NOX
Noxopharm Ltd.
0.09
-0.04
-30.77%
AU:NC6
Nanollose Ltd.
0.06
0.04
200.00%
AU:CMB
Regeneus Ltd.
0.52
0.11
26.83%
AU:AVE
Avecho Biotechnology Limited
AU:1AD
AdAlta Ltd.
0.01
-0.01
-50.00%

Amplia Therapeutics Corporate Events

Amplia Therapeutics Advances Narmafotinib Trials with Promising Results
Oct 28, 2025

Amplia Therapeutics has reported significant progress in its clinical trials for narmafotinib, a FAK inhibitor, showing improved outcomes in metastatic pancreatic cancer treatment. The company has achieved key regulatory milestones, including ethics approval for a new trial combining narmafotinib with FOLFIRINOX chemotherapy and securing a patent for its drug formulation, positioning it for further commercial development and potential partnerships.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials
Oct 28, 2025

Amplia Therapeutics has received a $3.77 million R&D tax rebate from the Australian Tax Office, which will support the progression of its clinical trials for narmafotinib, a FAK inhibitor. This funding will aid in advancing the ACCENT and AMPLICITY trials, which are exploring narmafotinib’s effectiveness in treating advanced pancreatic cancer, potentially enhancing Amplia’s position in the oncology pharmaceutical industry.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Expands U.S. Presence with New Investor Campaign
Oct 17, 2025

Amplia Therapeutics is expanding its U.S. presence by increasing investor engagement and awareness through a capital markets campaign. This initiative supports its ongoing Phase 2A clinical trial for pancreatic cancer and includes plans to uplist to the OTCQB market, aiming to broaden its U.S. investor base and enhance its market positioning.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial
Oct 8, 2025

Amplia Therapeutics has announced promising results from its ACCENT clinical trial, which tests the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown an improved Objective Response Rate of 33% compared to 23% with chemotherapy alone, and a mean duration on trial of 219 days, indicating enhanced efficacy and durability. Narmafotinib continues to demonstrate good tolerability, with no significant increase in chemotherapy-related side effects, positioning Amplia favorably in the cancer treatment landscape.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Announces Cessation of Securities
Oct 8, 2025

Amplia Therapeutics Limited announced the cessation of 5,626,000 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future growth prospects.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Secures Key US Patent for Cancer Drug Narmafotinib
Sep 30, 2025

Amplia Therapeutics has announced that the US Patent Office has allowed a key patent for its FAK inhibitor, narmafotinib, with a formal grant expected soon. This patent, already granted in several countries, extends narmafotinib’s protection until at least 2040, enhancing its commercial value. The patent describes a stable form of narmafotinib, which is being used in clinical trials for advanced pancreatic cancer, showing promising results. This development strengthens Amplia’s intellectual property portfolio and positions the company favorably in the pharmaceutical industry, particularly in the field of cancer treatment.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Announces Director’s Interest Changes
Sep 8, 2025

Amplia Therapeutics Limited announced a change in the director’s interest for Dr. Warwick Tong, as reflected in the attached Appendix 3Y. This update involves changes in the allotment and expiry of shares and options held by Dr. Tong. Such changes in director’s interests can impact stakeholder perceptions and reflect internal strategic adjustments within the company.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Updates Director’s Interest Notice
Sep 8, 2025

Amplia Therapeutics Limited has announced a change in the director’s interest notice for Dr. Christopher Burns, reflecting updates in his securities holdings. This announcement, authorized by the company’s secretary, highlights the ongoing management and regulatory compliance within the company, potentially impacting investor perceptions and stakeholder confidence.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Updates Director’s Interest Notice
Sep 8, 2025

Amplia Therapeutics Limited announced a change in the director’s interest notice for Dr. Robert Peach, reflecting a recent allotment of shares and options, as well as the expiry of certain options. This update is part of the company’s regulatory compliance and may impact the company’s stock dynamics and stakeholder interests.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Updates Director’s Interest Notice
Sep 8, 2025

Amplia Therapeutics Limited has announced a change in the director’s interest notice for Jane Bell, reflecting recent changes in her holdings of shares and options. This update is part of the company’s ongoing compliance with ASX listing rules and demonstrates transparency in its corporate governance practices.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Announces Cessation of Securities
Sep 8, 2025

Amplia Therapeutics Limited has announced the cessation of 2,355,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This announcement may impact the company’s capital structure but does not indicate any immediate operational changes or strategic shifts.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Begins New Pancreatic Cancer Trial with First Patient Dosed
Sep 3, 2025

Amplia Therapeutics has commenced a new pancreatic cancer trial, enrolling its first patient to test the combination of its FAK inhibitor, narmafotinib, with the chemotherapy regimen FOLFIRINOX. This trial, taking place in Australia and the US, aims to assess the safety, tolerability, and pharmacokinetics of narmafotinib, with dose-escalation expected to complete by Q1 2026. The trial’s initiation marks a significant milestone in the development of narmafotinib, which has shown promising results in preclinical studies and aims to improve survival rates in pancreatic cancer patients.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Announces Cessation of Securities
Sep 2, 2025

Amplia Therapeutics Limited has announced the cessation of 1,000,000 securities due to the expiry of options without exercise or conversion, effective September 2, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics’ FAK Inhibitor Gains USAN Approval
Sep 1, 2025

Amplia Therapeutics has announced that the United States Adopted Names (USAN) Council has approved ‘narmafotinib’ as the nonproprietary name for its lead FAK inhibitor, which is undergoing clinical trials for pancreatic cancer. This approval is a critical milestone in the drug’s commercial development, coinciding with the initiation of a clinical trial combining narmafotinib with FOLFIRINOX chemotherapy in the USA and Australia. The trial aims to explore the drug’s safety, tolerability, and efficacy, potentially enhancing Amplia’s positioning in the oncology market.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Issues New Unquoted Equity Securities
Sep 1, 2025

Amplia Therapeutics Limited has announced the issuance of new unquoted equity securities, specifically options expiring on September 30, 2028, with an exercise price of $0.30. This move is part of an employee incentive scheme, which may enhance employee retention and motivation, potentially impacting the company’s operational dynamics and stakeholder interests positively.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Advances Cancer Treatment with Successful Capital Raise
Sep 1, 2025

Amplia Therapeutics has successfully raised approximately $2.735 million through the issuance of 11,891,307 fully paid ordinary shares, following shareholder approval. This capital injection supports ongoing clinical trials of their promising FAK inhibitor, narmafotinib, which has shown efficacy in treating advanced pancreatic cancer. The trials, conducted in Australia and the US, aim to optimize dosing and further establish the drug’s effectiveness in combination with chemotherapy regimens, potentially enhancing Amplia’s position in the oncology market.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Announces Quotation of New Securities on ASX
Sep 1, 2025

Amplia Therapeutics Limited has announced the quotation of 1,021,740 new ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code ATX, effective from September 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Announces Quotation of New Securities on ASX
Sep 1, 2025

Amplia Therapeutics Limited has announced the quotation of 10,869,567 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code ATX, effective September 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could positively impact its strategic initiatives and stakeholders.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Launches New Pancreatic Cancer Trial in Australia
Aug 28, 2025

Amplia Therapeutics has initiated a new clinical trial in Australia to test the combination of its FAK inhibitor, narmafotinib, with the chemotherapy regimen FOLFIRINOX in patients with newly diagnosed metastatic pancreatic cancer. This trial, which is also set to commence in the USA, aims to explore the safety, tolerability, and efficacy of this combination, potentially offering improved outcomes for patients. The trial’s initiation underscores Amplia’s strategic focus on fibrotic cancers and its commitment to advancing innovative therapies in oncology.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Advances Cancer Treatment with Successful AGM Resolutions
Aug 27, 2025

Amplia Therapeutics Limited announced that all resolutions proposed at its Annual General Meeting were successfully passed. The company is advancing its ACCENT trial, which investigates the efficacy of its FAK inhibitor, narmafotinib (AMP945), in combination with other drugs for pancreatic cancer. This development could enhance Amplia’s position in the pharmaceutical industry, particularly in cancer treatment, and potentially benefit stakeholders by advancing treatment options for pancreatic cancer.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Advances FAK Inhibitor in Pancreatic Cancer Trials
Aug 27, 2025

Amplia Therapeutics has released a presentation by its CEO at the Annual General Meeting, highlighting the progress of its drug narmafotinib (AMP945), a FAK inhibitor showing promise in preclinical cancer studies. The ACCENT trial is currently assessing the drug’s efficacy in combination with other treatments for pancreatic cancer, with the trial being conducted across sites in Australia and South Korea.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Targets Pancreatic Cancer with Innovative FAK Inhibitors
Aug 7, 2025

Amplia Therapeutics Limited has released a presentation at the Bioshares Biotech Summit, highlighting their focus on targeting pancreatic cancer through their pipeline of Focal Adhesion Kinase (FAK) inhibitors. This strategic move underscores the company’s commitment to advancing treatments for fibrotic cancers and could potentially enhance its position in the biotech industry by addressing significant unmet medical needs.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Reports Promising Interim Results from ACCENT Trial
Aug 5, 2025

Amplia Therapeutics has announced positive interim data from its ACCENT trial, which is evaluating the efficacy of its FAK inhibitor, narmafotinib, in combination with standard chemotherapies for advanced pancreatic cancer. The trial results show significant improvements in progression-free survival and objective response rates compared to chemotherapy alone, indicating a promising advancement in treatment options for pancreatic cancer patients. The company is preparing for a potential pivotal phase 2b/3 trial, which could enhance its position in the oncology market and offer new hope for stakeholders in the healthcare sector.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Launches Share Purchase Plan to Raise Capital
Aug 1, 2025

Amplia Therapeutics Limited has announced a Share Purchase Plan (SPP) to raise $2.5 million, with the potential to accept over-subscriptions up to an additional $7.5 million. The SPP, which is not underwritten, is conditional on shareholder approval and is managed by Bell Potter Securities Limited. This move is part of Amplia’s strategic efforts to enhance its financial position and support its ongoing operations, potentially impacting its market standing and offering new opportunities for eligible shareholders and institutional investors.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Relocates Headquarters to Melbourne
Jul 31, 2025

Amplia Therapeutics Limited has announced a change in its registered office and principal place of business to Level 5, 90 William Street, Melbourne VIC 3000. This move is a strategic decision for the company, which is actively advancing its pipeline of FAK inhibitors. The change in location could potentially enhance operational efficiency and align with the company’s focus on developing treatments for fibrotic cancers and chronic diseases, thereby impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Advances Cancer Treatment Trials and Secures Funding
Jul 31, 2025

Amplia Therapeutics has reported significant progress in its ACCENT trial, demonstrating a 31% response rate for its FAK inhibitor narmafotinib combined with chemotherapy, surpassing the 23% rate of chemotherapy alone. The company is also initiating a new trial combining narmafotinib with FOLFIRINOX chemotherapy in the USA and Australia, supported by a recent $27.5 million capital raise to fund operations through 2027.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Gains Ethics Approval for Pancreatic Cancer Trial
Jul 30, 2025

Amplia Therapeutics has received Australian ethics clearance to initiate a Phase 2 clinical trial of its FAK inhibitor, narmafotinib, in combination with FOLFIRINOX chemotherapy for advanced pancreatic cancer patients. This trial, which follows US ethics approval, aims to identify the optimal dose of narmafotinib and will be conducted at sites in Australia and the USA. The trial’s outcome could enhance Amplia’s position in the oncology sector by potentially offering a more effective treatment option for pancreatic cancer, thereby impacting stakeholders positively.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025